Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B4ZQ
|
||||
| Former ID |
DIB001411
|
||||
| Drug Name |
SL-90.0571
|
||||
| Indication | Epilepsy [ICD10:G40] | Discontinued in Phase 1 | [1] | ||
| Company |
Synthelabo
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c12c(C3COC(OC3)CCCNC(=O)C)cccc1cc(cc2)OC
|
||||
| CAS Number |
CAS 139293-31-5
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium channel | Target Info | Modulator | [2] | |
| KEGG Pathway | Dopaminergic synapse | ||||
| Reactome | Interaction between L1 and Ankyrins | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002249) | ||||
| REF 2 | WO patent application no. 19990639849, Novel sodium channel drugs and uses. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.